Filing Analysis
Zentalis Pharmaceuticals announced the dosing of the first patient in its Phase 3 ASPENOVA clinical trial for azenosertib. The trial targets patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC) and is designed to support potential accelerated and full FDA approval.
Key Facts
- The Phase 3 ASPENOVA trial is a randomized, confirmatory clinical trial.
- The trial expects to enroll approximately 420 patients.
- Azenosertib monotherapy (400mg QD 5:2) will be compared against investigator's choice of standard-of-care chemotherapy.
- The trial design incorporates U.S. FDA feedback regarding requirements for accelerated approval and conversion to full approval.
- The primary indication is Cyclin E1-positive platinum-resistant ovarian cancer (PROC).
Zentalis Pharmaceuticals disclosed scientific data presented at the 2026 AACR Annual Meeting regarding its lead candidate, azenosertib. The presentations cover preclinical activity in triple-negative breast cancer and real-world outcomes in Cyclin E1-positive ovarian cancer.
Key Facts
- Presented data at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego (April 17-22, 2026).
- Exhibit 99.2 details preclinical models of WEE1 inhibitor azenosertib in Triple-Negative Breast Cancer (TNBC).
- Exhibit 99.3 analyzes real-world treatment patterns and outcomes for patients with Cyclin E1-positive Ovarian Cancer.
- The disclosures were made under Item 7.01 Regulation FD and are not deemed 'filed' for liability purposes.
Zentalis Pharmaceuticals announced the selection of 400mg QD 5:2 as the optimal monotherapy dose for azenosertib in ovarian cancer following positive interim Phase 2 data. The company plans to initiate a Phase 3 confirmatory trial in Q2 2026 and expects a topline readout for the Phase 2 trial by year-end 2026.
Key Facts
- Selected 400mg QD 5:2 as the optimal monotherapy dose for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer (PROC).
- The 400mg dose showed a 'meaningful and clearly differentiated response rate' over the 300mg dose with comparable safety.
- Initiation of the confirmatory ASPENOVA Phase 3 clinical trial is expected in Q2 2026.
- Expanded the DENALI Phase 2 trial to include Part 2c, broadening the study to patients previously treated with taxane-containing regimens.
- Company projects existing cash and marketable securities will fund operations into late 2027.
- Topline readout for the registration-intended DENALI Part 2 trial is expected by year-end 2026.
Zentalis Pharmaceuticals announced its full-year 2025 financial results and provided business updates on March 26, 2026. The information was disclosed via a press release furnished as an exhibit to the filing.
Key Facts
- Financial results reported for the fiscal year ended December 31, 2025
- Filing includes business updates alongside financial data
- Reported under Item 2.02 (Results of Operations and Financial Condition)
- Press release issued and furnished on March 26, 2026